Introduction
Tumor necrosis factor-α (TNF-α) is one of the soluble pro-inflammatory cytokines that mediate many inflammatory diseases. TNF-α has a molecular size of 17 kDa and exists in homo-trimeric form.
Through binding to cell surface receptors, TNFR1 and TNFR2, TNF-α exerts its versatile biological functions (Bradley, 2008) . Endogenous TNF-α expression is fairly low in healthy subjects (serum concentrations ~25 pg/mL), but increases by 2-3 fold in patients with inflammatory diseases (Manicourt et al., 1993) . Biologics that selectively neutralize TNF-α have shown great potential in the treatment of RA and other inflammatory diseases. The magnitude of their pharmacological effects depends not only on the binding and pharmacokinetics (PK) of these biologics, but also on the turnover of endogenous TNF-α in the body.
The PK of TNF-α were extensively examined in various animal species as an anti-cancer agent (Kojima et al., 1988; Ferraiolo et al., 1989; Greischel and Zahn, 1989; Zahn and Greischel, 1989) , but no quantitative characterization of its PK has been established. It was noted that TNF-α exhibited nonlinear pharmacokinetics. The clearance of TNF-α was attributed to: 1) a saturable elimination process mediated by TNFR binding and disposition, as demonstrated by concomitant administration of excess DMD # 74799 5 The first-generation minimal physiologically-based pharmacokinetic (mPBPK) models (Cao and Jusko, 2012 ) provide a suitable modeling platform for assessing pharmacokinetic features of small molecule drugs as well as smaller size proteins and peptides. Inheriting and lumping all major physiologic attributes from full PBPK models, the model includes blood/plasma and lumped tissue compartments connected in an anatomical manner. Distribution of drug molecules to tissues is assumed driven by Fick's Laws of perfusion and diffusion. In addition, the mPBPK models have the flexibility to include organs such as liver and kidney to account for their elimination mechanisms if necessary.
Classic allometric scaling approaches, assuming that different species share similar anatomical, physiological and biochemical properties, have been widely applied to anticipate drug PK across animal species (Mordenti, 1986) . This approach relates PK parameters (θ) across species to body weight (BW) with the equation:
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where a is the allometric coefficient and b is the allometric exponent. Integration of empirical allometric scaling principles into physiologically-based pharmacokinetic (PBPK) models provides a more advanced approach for interspecies PK prediction. This approach is applicable when PK measurements from one species are available. More importantly, PBPK and mPBPK models separate drug-and system-specific parameters. Thus species-specific physiological information, such as target expression and target binding affinity, can be utilized to account for the complexities of nonlinear drug disposition.
Our lab has assessed the feasibility of implementing allometric scaling principles into mPBPK models for relating interspecies pharmacokinetics of monoclonal antibodies (mAbs) (Zhao et al., 2015) .
Administration of therapeutic proteins via the SC route offers several advantages over IV including convenience, tolerance and prolonged exposure. However, less is known about the process of SC absorption for both mAbs and other protein therapeutics. The kinetics of SC absorption for protein This article has not been copyedited and formatted. The final version may differ from this version. drugs are fairly complicated, involving pre-systemic degradation and absorption via both blood and lymphatic transport. Uptake by lymph at SC injection sites is assumed to be the main route for their systemic absorption (Charman et al., 2001) . The relative contribution of lymph transport to systemic absorption varies with size and charge of the proteins (Swartz, 2001) , as well as the animal species and site of injection (McDonald et al., 2010; Kagan et al., 2012) .
In the present study, we examined the plasma pharmacokinetics of rhTNF-α in rats at relatively low doses and quantitatively characterized its pharmacokinetic properties with mPBPK models.
Experimental and literature-digitalized PK data of rhTNF-α in rats across wide a range of doses were applied for model fitting and to assess consistency across studies. The resulting model integrated with classic allometry was further applied for interspecies PK scaling in monkeys. In addition, a semimechanistic model was proposed and applied to explore the absorption kinetics of rhTNF-α following SC and other routes of administration.
remaining in the pumps were collected for stability tests. Serial blood samples were collected at 1, 1.5, 2, 2. 25, 2.5, 3, 4, 5, 6, 7, 8, 8.25, 8.5, 9 and 9 .5 h from the saphenous vein and at 10 h from the abdominal aorta upon sacrifice. The high dose SC infusion group (n = 4) received 117.4 μg/kg/day of rhTNF-α for 48 h using the Alzet micro-osmotic pumps (Model 1003D, infusion rate 1 μL/h), implanted as described above. Serial blood samples were collected at 1, 2, 3, 5, 10, 15, 17, 20 and 30 h from the saphenous vein and at 40 and 48 h from the abdominal aorta upon sacrifice. Blood samples were taken from at least 2 rats at each time point in all studies. Blood samples were immediately centrifuged at 2,000×g, at 4ºC for 15 min. The plasma fraction was aliquoted and stored at -80ºC.
Quantification of rhTNF-α. The rhTNF-α concentrations in plasma samples and the solutions remaining in the pumps were measured with the human TNF-α Quantikine HS ELISA kit (R&D Systems, Minneapolis, MN) following the instructions of the manufacturer. The standard curve was fitted to a four-parameter logistic model and ranged 0.5 -32 pg/mL. Between assay variability was tested with quality control (QC) samples (2 and 20 pg/mL) prepared by adding rhTNF-α to blank rat plasma, and was typically less than 15%. The cross-species reactivity was reported as minimal.
Literature Data Sources. Concentration-time profiles of rhTNF-α in rats were digitalized (Plot Digitizer, free software) from the literature for model development (Kojima et al., 1988; Ferraiolo et al., DMD # 74799 9 plasma, two lumped tissue compartments, and the kidney connected in an anatomical manner (Figure 1 ).
The model assumes that rhTNF-α is eliminated via saturable receptor-mediated disposition and renal filtration. The model equations are:
where Cp, C1, C2 and Ck are concentrations of rhTNF-α in plasma (Vp), two tissue interstitial fluid (ISF) compartments (V1 and V2) and kidney ISF (Vk), QCO is cardiac plasma flow, Qk is kidney plasma flow (Shah and Betts, 2012) , fd1 and fd2 are the fractions of QCO for V1 and V2, fdk is the fraction of Qk for Vk, Kp is the tissue partition coefficient, GFR is the glomerular filtration rate (Davies and Morris, 1993) , GSC is the glomerular sieving coefficient, and Vmax and Km account for nonlinear elimination. The GFR was set to zero in rats subjected to nephrectomy and Vmax was set to zero when excess TNF-β was present. All physiological volumes and flows used for rats in the mPBPK model are listed in Table 2 .
Allometric Scaling. The developed mPBPK model was scaled to generate rhTNF-α PK predictions in monkeys. Physiological flows and volumes of monkey were used and listed in Table 2 .
Classic principles of allometry were applied to scale model parameters between species (Eq. 1). The
This article has not been copyedited and formatted. The final version may differ from this version. Vmax was scaled to body weight with an exponent factor 0.75. Human TNF-α exhibits binding affinity for various animal species, and we assumed that the binding affinity (Km) of rhTNF-α to its receptors is the same in rats and monkeys. The ratio of V1 / (V1 + V2) was also assumed the same in both species.
Other parameters were shared between two species.
Absorption Model. A semi-mechanistic model was proposed for rhTNF-α absorption kinetics
given by different dosing routes. As depicted in the model scheme in Figure 2 , rhTNF-α reaches the blood through lymph uptake and other pathways including absorption via capillaries, but is also degraded at the injection site. Pre-systemic degradation is assumed saturable for SC doses. The PK data of rhTNF-α following other routes of administration were only available for one dose, thus linear degradation was assumed. The model was described as:
where Add, ALym, AOT1 and AOT2 are the amounts of rhTNF-α at the SC injection site, lymph and two transit compartments, VLym is the lymph volume and equals blood volume, La is the lymph flow rate measured by thoracic duct cannulation (0.6 mL/h (Kojima et al., 1988) ), kaL and kaO are absorption rate constants for rhTNF-α for lymph uptake and other routes, and kdeg is the pre-systemic degradation rate constant at the absorption site.
For SC administration:
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The amount of rhTNF-α that enters the systemic circulation (Input) is described as:
For animals that underwent thoracic duct cannulation, Input is:
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Bioavailability (F) and percentage absorption via lymph (%AbsLymph) were also calculated using: (Ferraiolo et al., 1989; Greischel and Zahn, 1989; Zahn and Greischel, 1989) . The extended first-generation mPBPK model was applied to simultaneously fit both experimental and literature reported rhTNF-α PK following IV doses. The model-fitted plasma concentration-time profiles of rhTNF-α were overlaid with observed data from different studies in rats (Figure 3 ). The parameter estimates are listed in Table 3 . Overall, the model was able to describe the plasma concentration profiles of rhTNF-α reasonably well despite the animal, study, digitizing, and assay variability. Interestingly, the model described the change of rhTNF-α plasma profiles quite well when mechanistic disturbances were introduced. The model predicted less impact on rhTNF-α PK profiles in nephrectomized rats compared with normal rats at lower doses, as the saturable receptor-mediated binding and disposition is the dominant elimination pathway ( Figure 3c ).
Also, in the presence of excess amounts of TNF-β, the receptor-mediated elimination of rhTNF-α is saturated and rhTNF-α is retained in the blood circulation for longer times ( Figure 3d ).
The fraction term fd is a hybrid parameter that describes both the ratio of the total cardiac plasma output distributing into each tissue and the permeability of that specific tissue. Therefore, if the sum of all fd is less than 1, the studied compound exhibits permeability issues. The fractions of cardiac plasma output flow for the two lumped tissue compartments (fd1 and fd2) are moderate and small (0.6663 and 0.0075), suggesting the occurrence of permeability rate-limited tissue distribution of rhTNF-α. The fdk could not be precisely estimated and thus was fixed at 0.8. The kidney is a highly perfused organ and the permeability of rhTNF-α in the kidney should resemble the tissues with greater fd. Also, the renal plasma flow (Qk) was used with the ratio of plasma flow distribution into the kidney of 1. Therefore, fdk falls in et al., 1972; Maack, 1974) . The receptor binding affinity of rhTNF-α is 0.5 nM when converted to molar concentration, which is within the range of binding affinity of TNF-α to TNFR1 (0.1 nM) and TNFR2
(greater or less than 0.1 nM) (Kull et al., 1985; Tsujimoto et al., 1985; Scheurich et al., 1986; Tartaglia et al., 1993; Van Ostade et al., 1993; Grell et al., 1998; MacEwan, 2002) . This indicates that the saturable elimination pathway of TNF-α is dominantly mediated by binding and disposition to TNFRs.
The estimated Vmax and Km values (3152 ng and 31.72 ng/mL) yield a maximum clearance of 100 mL/h, which controls rhTNF-α elimination at lower doses in comparison with renal filtration of 7 mL/h (GFR × GSC).
Allometric Scaling. The resulting mPBPK model for rats, integrated with allometric scaling, was used to project the pharmacokinetics of rhTNF-α in monkeys. The model-simulated concentrationtime profiles of rhTNF-α were overlaid with literature reported data in Figure 4 . The allometric predictions are in good agreement with the experimental PK in monkeys, with some under-prediction at higher doses following long term infusion. TNF-α was reported to induce glomerular damage in rabbits following 5-hour intravenous infusions at high doses (Bertani et al., 1989) , which possibly explains the discrepancy between model predictions and experimental measurements at higher rhTNF-α doses for 6.5-hour infusions. Surprisingly, the model very well predicts the changes of rhTNF-α PK in the ). This is reasonable since catabolic environments are considered similar at the SC and IM dosing sites.
This article has not been copyedited and formatted. The final version may differ from this version. Following SC and IM routes, appreciable portions of rhTNF-α are lost pre-systemically, whereas close to 100% of rhTNF-α is available for systemic absorption following IP, SW and GW doses. This might be explained by the presence of more proteases in skin versus the outer walls of the stomach and intestine. Also, the slower absorption rates through the lymph and bloodstream for SC and IM routes lead to prolonged retention of rhTNF-α at the dosing site and thus results in more pre-systemic degradation. In addition, the model suggests that less than 1% of rhTNF-α absorption occurs via lymph transport following SC routes, which agrees with previously studies (Bocci et al., 1986; Kagan et al., 2007) . On the other hand, following SW and GW doses, lymph transport accounts for more than 50% of the overall rhTNF-α absorption. This is due to the rapid lymph formation in the GI tract compared with other organs. Of the total lymph production, over 50% is formed in the GI tract (Alexander et al., 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. accounting for TNF-α catabolism because of the reticulo-endothelial system (RES). However, lung was reported to play a minimal role in rhTNF-α tissue uptake and elimination in rats (Pessina et al., 1995) . In another study with rabbits and monkeys, very little liver catabolism of rhTNF-α was observed by isolated organ perfusions (Pessina et al., 1987) . Both studies applied much higher doses of rhTNF-α and therefore the catabolism pathway of rhTNF-α mediated by TNFRs would be saturated.
Classic allometric scaling principles, assuming that PK attributes across species are related to body weight (Eq. 1), have been extensively applied for interspecies PK predictions of small molecule drugs. Such principles were extended for interspecies predictions with macromolecules. In general, example and further extends efforts to integrate simple allometry with mPBPK models for PK prediction of smaller size protein cytokines. Our mPBPK model mechanistically explains the nonlinear clearance of rhTNF-α, which allows reliable prediction of clearance in the monkeys with simple allometric rules.
More importantly, the mPBPK model includes all major contributing pathways for TNF-α elimination, and thus has the ability to make projections of changes of rhTNF-α PK when elimination pathways are disrupted under disease conditions such as kidney failure and altered expression of TNFRs with disease.
Our semi-mechanistic model explores the absorption kinetics of rhTNF-α following SC and other routes of administration. Absorption kinetics of mAbs and other therapeutic proteins are complicated and include pre-systemic degradation, direct absorption through capillaries, and indirect absorption via lymph transport. Despite efforts seeking to understand the key determinants of SC absorption kinetics, knowledge in this area is still incomplete. Our model delineates major components of protein absorption in a semi-mechanistic manner with limited experimental data and provides an attempt to improve the understanding of the attributes of protein absorption processes. A particular feature is the use and concordance of lymph concentrations, which enables the differentiation of the absorption pathways via lymph and other routes. Our findings about the lymph uptake contribution in SC administration agree with some previous studies with interferon, albumin, and erythropoietin (EPO) (Bocci et al., 1986; Kagan et al., 2007) , but contradict a report on PEG30-EPO (Wang et al., 2012) . This could be explained by the size and diameter of the molecules. PEG30-EPO has a molecular size of 70 kDa with a large diameter produced by pegylation, which confines its entry through capillaries. Also, lymph samples were collected by thoracic duct cannulation, which drains lymph generated from only parts of the body including upper extremities, trunk and hind legs (Tilney, 1971; Wang et al., 2012) .
Therefore, the SC dosing site matters. The datasets applied for our model development were from rats receiving SC doses at the upper back and rhTNF-α may enter systemic circulation via lymph at other entries rather than thoracic duct. The contribution of lymph uptake on overall absorption may be underrated.
Our model has some limitations. It was noted that pre-systemic degradation happened at both the SC dosing site and during lymph transport (Charman et al., 2000; Wang et al., 2012) . However, with rather limited data, model simplifications were made by lumping the pre-systemic degradation and assuming the degradation is only present at the SC dosing site. In addition, this model is not able to address the structural and physiological differences of skin between species, as well as the use of unrealistic large injection volumes in experimental animals, which further hinder reliable scale-up of absorption in man (McDonald et al., 2010) . A physiological model accounting for these unaddressed issues has been proposed in theory (Fathallah and Balu-Iyer, 2015) . However, more sophisticated animal studies and experimental data are required to allow application of such complicated models.
In conclusion, we characterized the pharmacokinetics of rhTNF-α in rats with mPBPK models and literature reported studies in rats (b -d) (Kojima et al., 1988; Ferraiolo et al., 1989; Zahn and Greischel, 1989) . Symbols are observed concentrations and lines depict model fittings using parameters from Tables 3 and 4 . The dotted line indicates the lower limit of assay quantification (LLOQ). Table 4 .
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